SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China
- Written by ACN Newswire - Press Releases
HONG KONG, Jan 18, 2021 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the first healthy
Read more //?#